Autolus Therapeutics Reports Third Quarter 2021 Financial Results and Operational ProgressGlobeNewsWire • 11/03/21
Autolus Therapeutics to Report Third Quarter 2021 Financial Results and Host Conference Call on November 3GlobeNewsWire • 10/25/21
Autolus Therapeutics provides an update on its manufacturing facility in Stevenage, UKGlobeNewsWire • 09/16/21
Autolus Therapeutics announces the appointment of John H. Johnson as non-executive chairman of its Board of DirectorsGlobeNewsWire • 09/15/21
Novaremed Expands its Pipeline of Non-opioid Treatment Candidates for Chronic Pain Indications Through Acquisition of Metys PharmaceuticalsBusiness Wire • 09/07/21
Autolus' Blood Cancer CAR T-Cell Therapy Receives Promising Innovative Medicine In UKBenzinga • 08/09/21
Autolus Therapeutics plc (AUTL) CEO Christian Itin on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/07/21
Autolus Announces Appointment of Edgar Braendle, M.D., Ph.D., as Chief Development OfficerGlobeNewsWire • 07/15/21
Autolus Therapeutics to Report Second Quarter 2021 Financial Results on August 5, 2021, and will Participate in the William Blair Biotech Focus Conference 2021 on July 14, 2021GlobeNewsWire • 07/08/21
Autolus Therapeutics Announces Innovation Licensing and Access Pathway (ILAP) designation for obe-cel for the treatment of relapsed/refractory adult B-cell ALLGlobeNewsWire • 06/15/21
Monday's Analyst Upgrades and Downgrades: Chipotle, CRISPR, Hess Midstream, iMedia, Kinder Morgan, Wendy's and More24/7 Wall Street • 06/14/21
Autolus Therapeutics' CAR T Cell Achieves 100% Complete Remission In Indolent B Cell Non-Hodgkin CohortBenzinga • 06/11/21
Autolus Therapeutics Presents New Data on obe-cel in r/r Indolent B Cell Lymphomas and gives an update of obe-cel in r/r Adult ALL at the European Hematology Association Virtual CongressGlobeNewsWire • 06/11/21
Autolus Therapeutics PLC Sponsored ADR (AUTL) Moves 35.5% Higher: Will This Strength Last?Zacks Investment Research • 05/13/21
Autolus Therapeutics to Present New Data on AUTO1 in r/r Indolent B Cell Lymphomas at the European Hematology Association Virtual CongressGlobeNewsWire • 05/12/21
Autolus Therapeutics Plc (AUTL) CEO Christian Itin on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/10/21
Autolus Therapeutics Reports First Quarter 2021 Financial Results and Operational ProgressGlobeNewsWire • 05/06/21
Autolus Therapeutics Receives Innovation Passport and entry into ILAP for AUTO4 for the treatment of T cell receptor constant region beta chain 1 (TRBC1) positive T cell lymphomasGlobeNewsWire • 04/20/21
Autolus Therapeutics announces appointment of Martin Murphy as Non-executive ChairmanGlobeNewsWire • 04/19/21